AGC
8.12.2022 16:01:35 CET | Business Wire | Press release
AGC, the provider of a wide range of solutions from automotive and display glass to the cutting-edge materials essential for next-generation mobility, will exhibit at CES2023, the world's leading technology trade show, being held in Las Vegas during January 3-8, 2023. The 3rd and 4th will be reserved for media and pre-show keynotes; the fair will be open to the public from the 5th. The company will exhibit 17 of its products, including several brand new releases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005064/en/
AGC‘s booth at CES2023 (#4377, Vehicle Tech & Advanced Mobility, LVCC - West Hall) (Graphic: Business Wire)
AGC has been a leading manufacturer of architectural, automotive and display glass for more than 110 years, supplying high-quality products worldwide. Today, the company leverages its technological expertise in the fields of glass, electronics, chemicals, and ceramics to provide a variety of cutting-edge materials and services that meet the growing demand for autonomous driving and other mobility services.
One of the highlights of AGC’s exhibits at CES will be the company’s FIR (far infrared) camera-compatible windshield, featuring special glass that allows far-infrared rays to penetrate, something which ordinary automotive glass does not. This allows sensor fusion of regular visible and FIR cameras mounted behind the windshield and reduces the risk of accidents involving pedestrians and cyclists at night or in bad weather.
Another highlight of the exhibit will be AGC’s glass composition and processing technologies; these provide the strength and optical capabilities needed to mount and deploy the cameras and the LiDAR (light detection and ranging) components required for autonomous driving. A wide range of other solutions will also be exhibited, including the 5G-sub6 Glass Antenna and the 3D Curved Cover Glass For Automotive Interior Displays. For a complete list, please refer to the Appendix.
Yoshinori Hirai, President & CEO of AGC, commented, “CES is one of the world's most influential technology trade shows, and we see it as the best stage on which to showcase AGC's capabilities to the world. We strongly believe our next-generation mobility-related products and solutions will create a buzz among CES visitors. The materials we offer have an appeal that can only be successfully conveyed when they are seen and experienced up close. We hope that as many people as possible will learn firsthand about the value we offer and make good use of our products.”
Please stop by our booth and see the various ways in which AGC is pushing the boundaries of technology. If you would like to interview an AGC spokesperson, please contact us.
Booth information
LVCC - West Hall
Vehicle Tech & Advanced Mobility
#4377
In the same West Hall there will be a separate booth (#6557) dedicated to our "Wideye" solutions and another for our "FeelinGlass" product (#6674).
About CES
Owned and produced by the Consumer Technology Association (CTA)®, CES® is the world’s most influential tech event; the proving ground for breakthrough technologies and global innovators where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. CES 2023 will showcase the latest technological innovations dedicated to addressing the world’s most pressing global challenges in support of the United Nations’ efforts to advance human security for all. Please visit https://www.ces.tech/ for further details.
About AGC Inc.
AGC Inc. (Headquarters: Tokyo, President & CEO: Yoshinori Hirai) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Building on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The Group employs some 56,000 people worldwide and generates annual sales of around 1.7 trillion Japanese yen (approx. US$ 12.3bn) through its operations in more than 30 countries and regions. For more information, please visit https://www.agc.com/en/index.html
Appendix (List of exhibited products and technologies)
Product Name |
Brand name |
Usage/Application |
Appearing for the first time? |
Features |
FIR (far infrared) camera-compatible windshield |
|
Automotive windshields |
Yes |
|
5 G-sub 6 Glass Antenna |
|
Automotive Glazing |
Yes |
|
3D Curved Cover Glass
|
|
Automotive Interior Display
|
No |
Anti-reflection / Anti-fingerprint coating |
Porous Aminosilica |
|
CO2 Direct Air Capture (DAC) / Acid gas removal /
|
Yes |
|
Thermal Conductive-Electrical Insulation Film |
|
Thermal interface material for power semiconductors |
Yes |
|
Super-Hydrophobic Glass |
|
Window and roof glass for mobility applications;
|
Yes |
|
Windshield damage detection smart sensor |
Jack by AGC |
Self-powered device that detects, diagnoses and notifies in real-time glass damage to windshields |
Prototype has been previously presented |
|
Glass B-Pillar With Invisible Sensor Integration |
Wideye by AGC |
Lateral integration of a LiDAR sensor in a B-Pillar made of infrared transparent glass |
Prototype has been previously presented |
|
Cover Glass |
EG-A1, EG-A2 |
LiDAR, Camera |
Yes |
|
Aspherical Glass Lenses |
Aspherical Glass Molded Lenses |
LiDAR, Camera, Projector, Optical communication, AR/VR/MR, Lighting |
No |
|
Optical Filter |
IR Pass Filter, Band Pass Filter, Mirror |
Cover/noise removal for LiDAR, Camera, UV disinfection, semiconductor manufacturing |
No |
|
Glass Ceramics Substrate |
GCHPTM |
LEDs, semiconductors, lasers |
No |
|
DOE and Diffuser |
DOE and diffuser |
ToF sensor, LiDAR, cameras, projectors, optical communication, AR/VR/MR, lighting |
No |
|
Anti-glare glass |
New AG (anti-glare) glass for high-definition panels |
High-definition notebook PCs, tablets and monitors |
Yes |
|
Chemically engineered high strength glass |
Dragontrail |
Cover glass for displays of smartphones, tablets, PCs, etc. (electronic devices requiring cover glass) |
No |
|
FWA antenna |
"5G Millimeter Wave Transparent Antenna for FWA " |
Antenna is thin and transparent,
|
No |
|
Transparent Reflector Fence |
|
Local 5G networks |
Yes (overseas) |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221204005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom